Innervate Therapeutics Ltd - Accounts to registrar (filleted) - small 23.2.5

REGISTERED NUMBER: 11922783 (England and Wales)

INNERVATE THERAPEUTICS LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2023

Page

Balance Sheet

1

CURRENT ASSETS

102,370

197,030

CREDITORS

Amounts falling due within one year

(127,086

)

(210,866

)

NET CURRENT LIABILITIES

(24,716

)

(13,836

)

TOTAL ASSETS LESS CURRENT LIABILITIES

(24,716

)

(13,836

)

CREDITORS

Amounts falling due after more than one year

75,000

75,000

NET LIABILITIES

(99,716

)

(88,836

)

CAPITAL AND RESERVES

(99,716

)

(88,836

)

NOTES TO THE FINANCIAL STATEMENTS

1.	STATUTORY INFORMATION

Innervate Therapeutics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

11922783

Registered office:

St Brandon's House

29 Great George Street

Bristol

BS1 5QT

2.	AVERAGE NUMBER OF EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2022 - 3 ) .

3.	CONTINGENT LIABILITIES

During the period the company received grant funding in relation to pre clinical and clinical trials undertaken. The purpose of the grant is to support ongoing eligible project expenditure. Should any conditions of the grant be contravened or unspent, then the grant could become repayable to the funder.

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 11 October 2023 and were signed on its behalf by:

Mrs S Kane - Director